FORTREA HOLDINGS DL-,001 Aktie

Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » Więcej na de.investing.com

Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Więcej na finanzen.net

Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Więcej na de.investing.com